CD274 and soft tissue sarcoma: In palliative therapy, not only were overall PFS and OS measured, but the efficacy between different subgroups was also compared, such as PD-L1-negative versus PD-L1-positive patients, osteogenic sarcoma versus soft tissue sarcoma patients, patients with adverse events versus those without adverse events, and patients treated with monotherapy versus those treated with combination therapy.